Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.53 |
| ▸ | CDC25B | P30305 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.49 |
| ▸ | TACR2 | P21452 | 2/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.48 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7215148 | 1.00 | NT5E (0.60) | NT5EPTPN1CDC25BLMNAPTPN2 | |
| SCHEMBL24371822 | 1.00 | NT5E (0.60) | NT5EPTPN1CDC25BLMNAPTPN2 | |
| SCHEMBL18744566 | 0.99 | NT5E (0.59) | NT5EPTPN1CDC25BLMNAPTPN2 | |
| SCHEMBL8222985 | 0.99 | NT5E (0.59) | NT5EPTPN1CDC25BLMNAPTPN2 | |
| SCHEMBL4185190 | 0.99 | NT5E (0.59) | NT5EPTPN1CDC25BLMNAPTPN2 | |
| SCHEMBL7174275 | 0.99 | NT5E (0.59) | NT5EPTPN1CDC25BLMNAPTPN2 | |
| SCHEMBL7174279 | 0.99 | NT5E (0.59) | NT5EPTPN1CDC25BLMNAPTPN2 | |
| SCHEMBL8227939 | 0.99 | NT5E (0.59) | NT5EPTPN1CDC25BLMNAPTPN2 | |
| SCHEMBL8227941 | 0.99 | NT5E (0.59) | NT5EPTPN1CDC25BLMNAPTPN2 | |
| SCHEMBL22582812 | 0.96 | NT5E (0.61) | NT5EPTPN1CDC25BLMNAPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642206-B2 | Useful in treating a wide variety of diseases including infections, infestations, neoplasms and autoimmune diseases | ICN PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6573248-B2 | Therapeutic agent for use in the treatment of tumors, infections, infestation and autoimmune disease | ICN PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| EP-1027359-A4 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6130326-A | Monocyclic L-Nucleosides, analogs and uses thereof | ICN PHARMACEUTICALS, INC. (US) | 2000-10-10 | — | — | US | disclosed |
| EP-1027359-A2 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN Pharmaceuticals, Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1998016186-A2 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095033-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | NT5E 38/4885PTPN1 1074/4885CDC25B 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.